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Introduction: Cardiovascular (CV) disease is the major cause of death
among renal transplant recipients (RTR). Unlike end stage renal disease, it is
unknown whether echocardiographic abnormalities are useful to identify RTR
with high cardiovascular and risk of death.
Objectives: To characterize the metabolic profile, risk of major adverse
cardiac events (MACE) and death in a population of RTR. Characterize cardiac
function and morphology. Determine which echocardiographic abnormalities
predict the risk of MACE and death.
Methods: Retrospective review of 107 RTR in follow-up at our institution, with
a functioning and stable graft for longer than 12 months and an echocardio-
graphy performed in the last year. Risk of MACE and death using a CV risk
calculator specific for RTR and echocardiographic parameters were analysed.
Results: Among 107 patients followed at our institution (57.9% males,
50.4 ! 13.9 years old), 7-years risk for MACE was >10% in 30.9% of patients
and 7-years risk for death >10% in 56.1%. Left ventricular hypertrophy (LVH)
was present in 55.1%, diastolic dysfunction in 39.3%, dilated left atrium (LA) in
53.3%, high pulmonary artery systolic pressure (PASP) in 29.0%, valvular
calcifications in 22.4% and moderate to severe mitral regurgitation (MR) in
3.7%. Mean Ejection fraction was 68.36 ! 6.87%. Univariate analysis showed
an increased risk of MACE in patients with LVH [6.9% vs. 14.5% (p 10% and
valvular calcifications [OR 3.499 (1.115–10.982, p = 0.032)] and elevated
PASP [OR 7.954 (2.412–26.238, p = 0.001)]. Risk for death>10% in multivari-
ate analysis had an independent association with diastolic dysfunction [OR
3.909 (1.261–12.115, p = 0.018)] and with elevated PASP [OR 4.319 (1.201–
15.535, p = 0.025)].
Conclusion: Echocardiographic abnormalities identify RTR at increased risk
of MACE and death. Valvular calcifications and elevated PASP are significant
predictors of MACE whereas Diastolic dysfunction and elevated PASP are
significant predictors of death.
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Infection was the principal cause of death after the first year of kidney
transplantation (KTx), but the cause of early mortality, was not well described in
the actually.
We performed a retrospective, unicentric analysis of mortality in the first
30 days after KTx during January 2000 to May 2014. Older patients than
18 years who received single or combined organ transplantation (COT) from
deceased or living donors were included. Data were obtained from medical
records and necropsy evaluation. Variables analyzed were age, sex, race,
ERSD etiologies, time in dialysis, BMI, living or deceased donor, induction
therapy and COT. Statistical analysis was done by Mann-Whitney test, Chi-sq
test and Step-wise logistic regression.
In this period, a total of 2390 patients were transplanted in our center.
Mortality within the first 30 days after KTx occurred in 87 patients(3.5%),
majority of them, were male(60%), white (59%), mean age was 53 ! 12 years
and a mean time of dialysis were 52 months. The principal ERSD etiologies
were DM (29%), Hypertension (24%) and Glomerulonephritis(22%) and high
percentage was transplanted with deceased donors (92%). The most frequent
cause of death was infection with 31 cases (36%) followed by cardiovascular
(23%), hemorrhagic (21%) and other causes (20%). We observed a raising
trend increase of death by infection causes (DIC) during the period analyzed
Chi-sq 9.09, p = 0.003, as opposed to cardiovascular and hemorrhagic
causes, that’s tended to reduce. Patients with DIC more frequently dead after
the 7th day of hospitalization (73% p = 0.006), were more often COT patients
(58% p = 0.06) and had less dialysis time before KTx(P = 0.07), when
compared with other causes of dead. In multivariate analysis the differences
between DIC and others death causes were COT p = 0.02 OR4.63 and death
after 7th day of KTx p = 0.002 OR0.18.
Death by infectious diseases took a longer time to be set as a principal
cause of mortality and were associated to more complexity surgery, as COT.
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Introduction: Transplantation is the optimal form of renal replacement
therapy for suitable patients with end stage renal disease. Long term outcomes
improve when the time spent on dialysis is minimised, and individuals with
prolonged waiting times can become unfit for transplantation. Those with pre-
existing HLA antibodies often wait a disproportionately long time.
Methods: All patients in Northern Ireland (NI) active on the UK deceased
donor renal transplant waiting list on 1 Jan 2013 were ranked according to
waiting time. All waiting longer than 5 years were identified and those that were
very highly sensitised reviewed. Antibodies that were currently not detectable
or present at low titres were removed from the unacceptable antigens listed
with NHS Blood and Transplant.
Results: There were 30 patients waiting longer than 5 years. The mean
waiting time for transplantation was 8 years 5 months, (range 5 years.
1 month – 21 years. 3 months) and mean panel reactive antibody sensitisation
was 71%, (range 0 – 100%); 16 (53%) were very highly sensitised (>95%
antibodies). The registered unacceptable antigens were altered in 10
(33%).Within 24 months, there were 30 transplants in 28 (93%) patients, one
is now unfit for transplantation and one is currently suspended. 8 (27%) were
from living donors. Alemtuzumab was given in 9 transplants and Rituximab in 2.
The 12 month graft survival was 87%. Of the 4 grafts that failed: 2 had primary
non-function due to donor characteristics, 1 failed due to non-recovery of
recurrent episodes of AKI after 5 months, and 1 failed at 10 months due to
recurrent anti-GBM disease. Two of these patients have seen been trans-
planted successfully. 12 month patient survival was 100%. In NI there are
currently only 2 patients waiting longer than 5 years.
Conclusion: A proactive approach to highly sensitised patients can enhance
the opportunities for transplant and should be considered for those with high
HLA antibody levels before they have a prolonged duration on dialysis.
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Introduction: This study aimed to determine the most recent results of kidney
transplantation (KT) from donation after brain death (DBD) and circulatory
death (DCD). Primary endpoints were graft and patient survival, and graft
function. Acute rejection and post-operative complications were assessed as
secondary endpoints.
Patient and Methods: This retrospective mono-center review consisted of
226 DBD- and 104 DCD-KT between 2008 and 2014.
Results: Graft survival was comparable between two groups (95.1 vs. 91.1%
at 1 year, 92.8 vs. 91.1% at 3 years and 89.2 vs. 91.1% at 5 years). 46% and
40% of graft loss were attributed to patient death with a functioning graft and
rejection. Patient survival was comparable between 2 groups (97.8 vs. 95.1%
at 1 year, 94.1 vs. 91.2% at 3 years, and 89.6 vs. 82.3% at five years). Etiology
of patient death included cardiac arrest (16.7%), infection (16.7%), cancer
(13.3%), and unknown cause (46.7%). Delayed graft function occurred in
14.6% of DBD- and 30.8% of DCD-KT (p = 0.001). Primary non function was
encountered in 2.6% DBD- and 4.8% DCD-KT (p = ns). Graft function was
worse in DCD than DBD up to 3 months post-transplant (p = 0.034), however,
no difference existed afterwards. Biopsy-proven acute rejection was found in
12.8% and 13.5% of DBD- and DCD-KT during an average 3 months post-
transplant (p = ns). This rate was 7.1% vs. 8.9% on surveillance biopsy
performed between 3 and 6 months post-transplant (p = ns). Post-operative
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complication rate was comparable between 2 groups, concerning patient
death, reoperation, transfusion, perirenal hematoma, macroscopic hematuria,
urinary obstruction, wound problem, and infection. Nevertheless, contamina-
tion of preservation solution occurred more commonly in DCD than DBD (0.4%
vs. 3.8%, p = 0.036).
Conclusions: Despite worse early graft function, DCD-KT was not inferior to
that originating from DBD up to 5 years post-transplant, therefore deserves to
be used.
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Background: Validated surrogate endpoints for long term kidney graft
function are needed in clinical kidney transplantation trials. This study
evaluates the association between initial kidney graft recovery and graft
function 1 year posttransplant.
Methods: A single centre, observational, cohort study including 100 kidney
transplants followed 1 year at Aarhus University Hospital. All p-creatinine (p-cr)
values at time of transplantation and 30 days posttransplant were registered
along with relevant patient characteristics. In case of temporary dialysis
posttransplant, p-cr was gathered until 30 days after the last dialysis. One-year
p-cr and graft outcome were registered and in case of death or graft loss,
patients were excluded from the analysis (n = 4). The observed, time
dependent changes in p-cr were modulated for each, individual patient by an
exponential, logistic, or a linear model, and the time to a 50% decrease in p-cr
was estimated. eGFR 1 year posttransplant was calculated using the simplified
Modification of Diet in Renal Disease (MDRD) formula. A multiple linear
regression model was used to analyse the association between the time to a
50% drop in p-cr and eGFR after 1 year.
Results: The time to a 50% drop in p-cr correlated negatively with eGFR at
1 year (n = 96, r = !0.375, beta = !0.112, p = 0.0002). The correlation
persisted when corrected for donor type, recipient age, gender, initial p-
creatinine level, and cold ischemia time (n = 90, p = 0.018). A positive
correlation between the time to a 50% drop in p-cr and the total days of
hospitalisation 30 and 365 days posttransplant, as well as the number of
performed ultrasounds and kidney biopsies 90 days posttransplant, was also
found.
Conclusion: Early graft function differences may be important for long-term
outcome. Time to a 50% drop in p-cr might be used as a surrogate marker in
renal transplant studies, and includes both patients with or without temporary
posttransplant dialysis need.
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Background: In general, the recommended tacrolimus (Tc) initial dose is
calculated per kg of body weight and fixed at 0.1 mg/kg/dose BID. Some
observations suggest that in selected groups of patients such dosing may result
in Tc tocixity in the early posttransplant period. The aim of our study was to find
the factors increasing an initial Tc trough level.
Methods: We performed the retrospective analysis (2000–2013) of 468
consecutive kidney transplant recipients initially treated with immunosuppres-
sive regimen containing tacrolimus BID, mycophenolate, and steroids. The
analysis included the first assessment of Tc trough levels and patient-related
factors that might affect the pharmacokinetics of Tc.
Results: The mean initial Tc dose was 0.095 " 0.002 mg/kg BID. The
analysis revealed that recipient’s age, BMI, and pretransplant diabetes, but not
gender or residual diuresis are explaining the veariability of initial Tc trough
level. Recipients >70 years old had 46% greater Tc initial trough levels than
those 30 years or less (16.5 " 7.1 vs. 11.3 " 6.3 ng/ml, p < 0.001). Higher
concentrations were also observed in diabetics (16.6 " 8.0 ng/ml) than
nondiabetics (13.5 " 6.7 ng/ml), and in overweight (15.3 " 7.0 ng/ml) and
obese (16.9 " 5.9 ng/ml) than normal weight (13.0 " 6.7 ng/ml) and under-
weight (10.9 " 7.2 ng/ml) patients. The association between Tc trough level
and BMI was independent from the influence of age. Additionally, there was no
influence of early graft function on Tc trough level.
Conclusion: The reduction of recommended fixed Tc initial dose should be
considered in the elderly, diabetics, and overweight/obese kidney transplant
recipients.
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